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Abstract. Transforming growth factor-ß, (TGF-ßl) has
previously been implicated as a potential negative auto-
crine or paracrine growth regulator of certain cell
types (Arteaga, C. L., R. J. Coffey, Jr., T. C. Dugger,
C. M. McCutchen, H. L. Moses, and R. M. Lyons.
1990. Cell Growth & Differ. 1:367-374; Hafez, M. M.,
D. Infante, S. Winawer, and E. Friedman. 1990. Cell
Growth & Differ. 1:617-626; Glick, A. B., K. C. Flan-
ders, D. Danielpour, S. H. Yuspa, and M. B. Sporn.
1989. Cell Regulation. 1:87-97). This is based mainly
on experiments assessing the effects ofexogenous
TGF-ß1 or neutralizing antibodies to TGF-ß1 on nor-
mal or tumor cell proliferation in vitro. However, di-
rect evidence demonstrating such a negative regulation
of tumor cell growth in vivo is still lacking. To over-
come this problem we have constructed and used an
antisense expression vector for TGF-ß, as a means of
regulating endogenous TGF-ß1 expression in tumor
cells. Antisense-transfected FET human colon car-
HE transforming growth factor-ßs (TGF-ß)1 are a
family of hormonal-like polypeptide growth factors
withmultifunctional effects onavariety oftarget cells
(Massagu6, 1990; Spornetal., 1987). Thetypeofeffect elic-
itedby the TGF-ßs is afunctionofthe target cell exposedto




known human TGF-ß (ß1, 02, and 03) genes. Although
the three forms of TGF-ß show some differences in po-
tency (Graycar et al., 1989) and are differentially regu-
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cinoma cells showed a fivefold reduction in TGF-01
mRNA and 15-fold reduction in TGF-ß1 secretion. Anti-
sense mRNA was detected in transfected cells by an
RNase protection assay. Compared to control cells,
cultured antisense-transfected cells showed a reduction
in lag phase time rather than a change in doubling
time. Cloning efficiencies of transfected cells were
four times greaterthan controlcells in anchorage-inde-
pendent assays. Control cells did not form tumors at
5 x 105 in athymic nude mice. Antisense-transfected
cells formed tumors in 40% of animals injected. At
higher inocula (1 x 106 cells) antisense-transfected
cells formed tumors in 100% of animals injected, but
control cells still failed to form tumors. These results
show that TGF-01 acts as a negative growth regulator
of human colon carcinoma cells in vivo as well as in
vitro. Acquisition of partial or full resistance to such
inhibitory effects may therefore contribute to tumor
development and progression.
lated (Bascom et al., 1989), they have similar biological
effects.
Almost all cell types and tissues express one or more of
theTGF-ßmRNAs(Deryncketal., 1988). AlthoughTGF-,ßs
are released from cells via a constitutive secretion pathway,
most ofthe secreted materialhas been shown to be released
in a latent, inactive form (Lawrence et al., 1985). Despite
the predominance oflactency in conditionedmedia contain-
ing secreted TGF-ßs from cultured cells, there is evidence
thata sufficient portion to actinanautocrinemanner is pres-
ent in themedium ofat least some cell lines (Arteaga et al.,
1990; Hafez et al., 1990; Glick et al., 1990; Singh et al.,
1990).
Most studies of TGF-ß, autocrine-negative effects have
depended on indirect stimulationoftarget cells by neutraliz-
ing antibodies to TGF-ß1. There are some distinct limita-
tions in using neutralizing antibodies to demonstrate auto-
187crine TGF-ß inhibitory activity in transformed cells. One of
these is the low levelofinduction ofproliferation or enhance-
ment of anchorage-independent growth seen in these studies
as a result of neutralization (Arteaga et al ., 1990; Hafez et
al., 1990) . This may be due to relativelyweak effects of auto-
crine TGF-ßon proliferation or to the loss ofneutralizing an-
tibody activity during the course of an experiment. A second
and perhaps more important limitation is the difficulty ofex-
tending neutralizing antibody experiments from tissue cul-
ture to animals to determine autocrine effects of TGF-ß on
the biological behavior of tumors. Consequently, we have
constructed an expression vector for an antisense mRNA to
the human TGF-ß1 cDNA to study the autocrine effects of
TGF-ß, in a human colon carcinoma cell line (designated
FET) which expresses TGF-ß1 mRNA, but has no detect-
able TGF-ß2 or TGF-ß3 mRNA. Antisense approaches have
been successfully used to study the functions of a number of
oncogenes (Inouye, 1989) and products associated with ex-
tracellular matrix degradation (Khokha et al., 1989).
The FET cell line was isolated from a well-differentiated
primary human colon carcinoma and has been extensively
characterized. The line is continuously maintainedin a com-
pletely defined serum-free medium (Wan et al., 1988) and
has retained differentiated characteristics in tissue culture in-
cluding basolateral polarity and the ability to form transport
domes (Chantret et al., 1988). The parental cell line does not
readily form colonies in soft agarose and is only weakly tu-
morigenic in athymic nude mice (Brattain et al ., 1984). The
cell line displays all three types of known TGF-ß receptors
or binding proteins and like most well-differentiated colon
carcinoma cell linesis inhibited by the addition of exogenous
TGF-ß to growing cultures (Hoosein et al ., 1989) . Another
characteristic of differentiated colon carcinoma cell lines is
the ability of exogenous growth factors to stimulate quies-
cent cells to undergo DNA synthesis, while quiescent poorly
differentiated cell linesare unresponsiveto exogenous growth
factors (Mulder and Brattain, 1989) . TGF-ß attenuates the
growth factor-mediated stimulation of DNA synthesis in
quiescent FET cells (Mulder et al ., 1990a,b). Thus, it would
be expected that constitutive expression of TGF-ß, antisense
mRNA would result in significant biological changes with
respect to differentiation, growth, and tumorigenicity of
FET cells if TGF-ß, was contributing to the control of these
biological properties in an autocrine manner.
This report describes the biological consequences of mo-
lecular abrogation ofTGF-ß, expression in vitro and in vivo.
The constitutive expression of TGF-ß1 antisense mRNA in
FET cells increased anchorage-independent growth and en-
hanced tumorigenicity in athymic mice.
Materials andMethods
Cells and Culture
The FET human colon carcinoma cell line was established in vitro from
a primary tumor as previously described (Brattain et al., 1984). Cells were
maintained at 37°C in a humidified atmosphere of5% CO2 in McCoy's 5A
medium (Gibco Laboratories, Grand Island, NY) supplemented with 4
mg/ml transferrin, 10 ng/ml EGF, and 20 wg/ml insulin (serum-free
medium) as previously described (Boyd et al., 1988) . Mink lung epithelial
cells (ATCC CCL64) werepurchased from American Type Culture Collec-
tion (Rockville, MD) and maintainedin McCoy's 5A medium supplemented
with 10% FBS.
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Transforming Growth Factor-ßs andAntibodies
Human recombinant TGF-ß1 was provided by Dr. Tony Purchio from On-
cogen (Seattle, WA). Porcine platelet TGF-ß2 was purchased from R & D
System, Inc. Both TGF-ß, and TGF-02 were stored in 4 mM HCl and
1 mg/ml BSA at a concentration of2,000 ng/ml before being diluted to the
final desired concentration with tissue culture medium.
Chicken anti-porcine TGF-ß, neutralizing antibody was purchased from
Oncomembrane (Seattle, WA). The antibody is >90% pure as determined
by SDS-PAGE. No cross-reaction with TGF-ßZ has been observed. Rabbit
anti-porcine TGF-ß2 neutralizing antibody, purified by protein A chroma-
tography was purchased from R & D System Inc. (Minneapolis, MN). This
antibody does not cross react with TGF-ß1.
Construction ofHuman TGF-ß, cDNA Clone and
Antisense Expression Vector RLDN-RSVAS
Total RNA was prepared from human monocytes by the guanidinium
isothiocyanate method (Chirgwin et al., 1979) and poly(A)+RNA was
purifiedby oligo (dT)-cellulose chromatography (Aviv et al., 1972). cDNA
was prepared using a cDNA synthesis kit (Boehringer Mannheim Diagnos-
tics, Inc., Houston, TX) andcloned into lambda ZAParms (Strategene, San
Diego, CA). Approximately 1 x 106 clones were screened (Wood et al.,
1985) using oligonucleotides specific for TGF-ß, sequences (Derynck et
al., 1985) . One positive clone was isolated and confirmed by DNA sequenc-
ing (Sanger et al., 1977) to be human TGF-ß1. This clone was digested
with Narl and NcoI. The resulting 1.7-kb fragment (which includes -400
by of 5' untranslated region, 83 by of 3' untranslated region, and 1,173 by
of coding region) was inserted in opposite orientation into the expression
cassette of the plasmid vector RLDN. The RLDN vector was originally
constructed by J. Trill and M. Reff (Smith, Kline, and Beechman Pharma-
ceuticals, Philadelphia, PA) for the stable integration, amplification, and
expressionofheterologous proteins in mammalian cells. Inthisvector, tran-
scriptionofthecDNA iscontrolled by the Rous sarcomavirus long-terminal
repeat promoter (Gorman et al., 1982) while a termination signal is pro-
vided by the bovine growth hormone 3'-flanking sequence (Pfarr et al.,
1985). This vector also contained a bacterial neomycin phosphotransferase
gene (NEO) expression cassette forG418 selection (Southern et al., 1982).
The human TGF-ß, antisense expression vector was designated RLDN-
RSVAS.
Cell Transfection and Isolation of
Stable Transfectants
FET cells (2 x 106) harvested at mid-log phase growth were transfected
either with the RLDN-RSVAS plasmid (5 Ag) or with the plasmid vector
RLDN (5 ug). Electroporation was carried out at 250 V, 960 pFD with a
gene pulser (Bio-Rad Laboratories, Cambridge, MA). Cells were allowed
to grow for 2 d before being subjected to selection for the ability to grow
in medium containing 600 pg/ml geneticin (G418 sulfate, Gibco Labora-
tories). Stable cell clones resistant to G418 sulfate were obtained after
2-3 wk growth with the drug-containing medium. These populations of
transfectants (-103 individual clones) were pooled, expanded, and desig-
nated as FET NEO and FET RSVAS, respectively.
Southern Blot HybridizationAnalysis
DNA isolation, restriction endonuclease digestion, 0.8% agarose gel elec-
trophoresis, and Southern blotting onto Nytran membrane (Schleicher &
Schuell, Inc., Keene, NH) were all performed as described by Sambrook
et al. (1989). Labeling of probe, hybridization, and wash conditions were
performed as described for RNA analysis below.
Northern Blot and RNase Protection Analyses
Total RNA was prepared from cultured cells by the guanidium isothiocya-
nate method (Chirgwin et al., 1979). Poly(A)+RNA was isolated by one
pass oftotal RNA throughapoly (dT) column(Pharmacia LKB Biotechnol-
ogy Inc., Piscataway, NJ). Poly(A)'RNA (10 kg) was electrophoresed on
1.2%/2.2 M agarose-formaldehyde gels, transferred to Nytran membranes
(Scheicher & Schuell, Inc., Keene, NH) and hybridizedto appropriate 32p
labeled (Multiprime Labeling Kit; Amersham Corp., Arlington Heights,
IL) cDNA probes as previously described (Mulder, 1991). The cDNA
probes used were a 1.2-kb EcoRI fragmentof simian TGF-ß, cDNA (Shar-
ples etal., 1987), a 2.2-kb EcoRI fragment of human TGF-ß2 cDNA (pro-
vided by K. Coleman, Bristol-Myers Squibb Co.), and a 700-bp Pstl-
188EcoRV fragment of human TGF-03 (provided by N . Stirpe, Bristol-Myers
Squibb Co .) .
RNase protection experiments were performed as described by Zinn et
al . (1983) . A 243-bp PvuH-pvull fragment ofTGF-01 cDNA was isolated
from the RLDN-RSVAS expression vector and inserted into the pGEM3Z(-)
plasmid (Promega Biotec, Madison, WI) . The orientation of the insert in
the resulting plasmid was determined by DNA sequencing (United States
Biochemical, Cleveland, OH) . This plasmid was linearized by EcoRI and
used as a template to synthesize the sense strand TGF-01 RNA probe by
SP6RNA polymerase. DNase I was usedtodigest anyremaining DNA tem-
plate. Determinations of TGF-ß, antisense levels in total RNA samples (50
pg) were performed with 5 x 105 cpm of labeled probe . DriedRNA was
dissolved in 3011 ofRNA hybridization buffer (80% formamide, 400mM
NaCl, and 1 mM EDTA), denatured at 90°C for 10 min, and hybridized at
50°C overnight. RNase digestion buffer (300 Al) containing RNase A (40
,ug/ml) and RNase TI (3 U/ml) was used to degrade unhybridized probe at
37°C for 30 min . RNases were inactivated by adding 20 pl of 10% SDS,
50 Wg of proteinase K, and incubating at 37°C for 15 min . The RNA was
extracted with phenol/chloroform and analysis was performed by electro-
phoresis in 6%/8 M urea-polyacrylamide gels .
Growth Assays
Growth curves were performed in 96-well plates in 0.1 ml of serum-free
medium with inocula of either 101 or 10 3 cells . Relative cell number was
determined using theMTT assay (Carmichael et al ., 1987) . The values are
means t standard deviations derived from 16 wells .
For growth inhibition assays by TGF-ß,, FET NEO and FET RSVAS
cells were inoculated into 96-well plates at 101 or 103 cells per well in 0.1
ml of growth medium containing varying concentrations of TGF-ß, . The
growth inhibition was measured using the MTT assay as described above .
Mitogenesis assays were performed as previously described (Mulder and
Brattain, 1989) . Cells were plated in serum-free medium and allowed to
grow to saturation density andrenderedquiescent by addition offresh basal
McCoy's 5A medium for a 5-d starve period. Cells were then treated with
either fresh basal McCoy's 5A medium, fresh basal McCoy's 5A medium
together with the TGF-01 antibody (10 /ig/ml), fresh basal McCoy's 5A
medium plus TGF-01 (5 ng/ml), and fresh basal McCoy's 5A medium with
both TGF-01 (5 ng/ml), and TGF-01 antibody (10 tg/ml) . After 22 h,
[ 3H]thymidine was added for 1 h, followed by determination of TCA-
precipitable radioactivity . Values are means of three samples .
SoftAgaroseAssay
To study the effects of TGF-01 antisense expression on anchorage-
independent growth the FET transfectants, FET RSVAS cells, and RLDN-
transfected control cells (FET NEO) were compared for clonogenic poten-
tial in semisolid medium . Cells were suspended at 10° cells/ml in 1 ml of
0.4% sea plaque agarose in McCoy's 5A serum-free medium and plated on
top of 1 ml of0.8% agarose in the same medium in 35-mm culture plates.
Plates were incubated for 2.5-3.0 wk at 37°C with 5 % C02 in a humidified
incubator and stained with 2-(p-iodophenyl)-3-(p-nitrophenyl)-5-phenyl-
tetrazolium chloride (Sigma Chemical Co., St . Louis, MO) asdescribed by
Schaeffer and Friend (1976) to determine viability and to enhance the pho-
tographic contrast of the colonies from the agarose.
TGF-ßAssays
Total TGF-ß levels in serum-free conditioned medium from FET cells were
determined with the CCL64 mink lung growth inhibition bioassay (Daniel-
pour et al ., 1989) . Conditioned media collected at 72 h were tested for the
ability to inhibit CCL64 cell growth by theMTT assay in comparison with
the standard growth inhibition curves of the CCL64 cells by the TGF-01
and TGF-ß2, respectively. Neutralization of the conditioned media by the
TGF-01 neutralizing antibody (10 pg/ml) or TGF-02 antibody (10 Ag/ml)
was carried out to determine specificity. The amount of active TGF-ß pres-
entwas determined using untreated conditioned medium, while the amount
of total TGF-ß (including active and latent forms) was determined using
acid-treated conditioned medium . The cell numbers were determined when
the conditioned media were harvested . Acidification ofthe media was per-
formed as described by Arteaga et al . (1990) .
Subcutaneous Inoculations ofTumor Cells
Nude (nu-nu) mice (8-12-wk-old females) were purchased from the Jack-
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Figure 1 . Expression ofTGF-0
mRNA in colon cancer cells .
Poly(A)+mRNA (10 lAg) iso-
lated from FET, CBS, and
RKO colon cancer cells, was
electrophoresed on a 1.2%/
2.2 M agarose-formaldehyde
gel and transferred to a Ny-
tran membrane. The blot was
sequentially hybridized with
a 32P-labeled green monkey
TGF-0 1 cDNA probe (A), a
human TGF-02 cDNA probe
(B), and a human TGF-03
cDNA probe (C) . Hybridiza
tion was carried out as described in Materials and Methods. A 2.4
kb TGF-01 mRNA (A), 6.5 kb and 4 .1 kb TGF-ß1 mRNA (B), and
a 3.5 kb TGF-ß3 mRNA (C) are indicated .
son Laboratories (Bar Harbor, ME) . Tumorigenicity dose response curves
were generated for the control FET cell line (FET NEO) and the antisense
TGF-01 cell line (FET RSVAS) . Mice (five in each group) were injected
subcutaneously in the flank with either 1.25 x 105 , 2.5 x 105 , 0.5 x 106 ,
1 x 106, or 2 x 106 cells per animal, and the number of animals with
tumors (0.5 cm) in each group was scored every 2 wk .
Results
FETCellsExpress TGF-01 mRNA but Not TGF-ß1 or
TGF-03 mRNAs
Expression of TGF-ß 2 and/or TGF-N3 could potentially
complicate the interpretation of results in TGF-0 1 antisense
transfected cells since these factors have a high degree ofho-
mology (Massagu6, 1990) and might interact with TGF-ß,
antisense mRNA . Furthermore, TGF-ß2 and TGF-ß3 have
similar effects on target cells and can affect each other's ex-
pression (Graycar et al ., 1989 ; Bascom et al ., 1989) . Conse-
quently, there was concern that TGF-01 antisense effects
could be masked by compensatory action of TGF-ß 2 and
TGF-ß3 . FET colon carcinoma cells were chosen for these
studies because they expressed high levels of TGF-ß,
mRNA (Fig . 1) . Probes for human TGF-ß 2 and TGF-ß3 did
not detect mRNA for these genes under the same Northern
blot conditions (1014g poly(A)+mRNA) . FET cells secreted
a total of40 ng/10 6 cells per 72 h TGF-0 1 into tissue-culture
medium as determined by bioassay with -10% of the poly-
peptide in the active form (4.7 ng/106 cells per 72 h) . It was
189Figure 2 . The stimulation of
proliferation of FET cells af-
ter treatment with neutraliz-
ing antibody to TGF-01 in a
proliferation assay. FET cells
weretreated withthe indicated
amounts of TGF-ß, neutraliz-
ing antibody, cultured for4 d
and subjected to MTT assay.
Thegrowth stimulation ofFET
cells is represented by the per-
centageincrease ofcell growth
relative to untreated cells .The
values are means t standard





not possible to determine active TGF-ß2 protein within the
limits of the bioassay (<3 ng/106 cellsper 72 h) and there is
currently no methodology for the specific detectionof TGF-
ß3 levels in tissue culture medium or cells . An additional
advantage ofFETcells forthese studieswas their continuous
maintenance in a completely defined serum-free medium
(Wan et al ., 1988), thus eliminating any serum effects with
respect to exogenous TGF-0 1 or TGF-ß binding proteins .
TGF--ß, IsaNegative AutocrineGrowth Regulator in
FETCells
TGF-01 has been shown to be a negative growth regulator
in a number of colon carcinoma cell lines including FET
cells . This negative regulation has been shown to occur at
the levelofcell proliferation(Hoosein et al ., 1987, 1989)and
the initiation ofDNA synthesis from quiescence (Mulder et
al ., 1990a,b) . Therefore, ifTGF-01 were acting as a nega-
tive autocrine growth regulator in the FET cells (as sug-
gested by the levels of active TGF-0 1 secreted into FET cell
medium), one would expect that neutralizing antibody to
TGF-01 would have the effects of increasing FET prolifera-
tion and increasing the amount of DNA synthesis in cells
released from quiescence .
Neutralizing antibody specific for TGF-0 1 was found to
increase cell proliferation in a dose-dependent manner from
1-50 pg/ml when added to thegrowth medium of FET cells
(Fig . 2) . As in other studies with human cancer cells (Ar-
teaga et al ., 1990 ; Hafez, 1990), theincrease in proliferation
obtained was rather modest as only a 1.75-fold stimulation
wasobtained atthehighest antibody concentrationused . The
antibody was also effective in stimulating DNA synthesis in
FETcells released from quiescence by the addition of fresh
medium (Fig . 3) . In contrast to the proliferation results, the
addition of neutralizing antibody at the same time as fresh
medium addition showed an increase of almost fourfold in
['H]thymidine incorporation . Addition of exogenous TGF-
01 (5 ng/ml) along with the neutralizing antibody brought
the levels of [3H]thymidine incorporation back down to
control levels for untreated cells. Quiescent cells treatedwith
exogenous TGF-0 1 (5 ng/ml) at the same time as addition of
fresh medium showed only 15% as much incorporation of
[3H]thymidine into DNA as untreated control cells .
These two experiments showed that FET cells are nega-
tively regulated by TGF-0 1 in an autocrine manner. The
demonstration of autocrine TGF-0 1 activity in FET cells
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Figure 3 . The stimulation of
DNA synthesis in quiescent
FETcells by TGF-01 antibody.
Cells weremade quiescent and
then released from quiescence
by the addition of fresh medi-
um or medium plus the indi-
catedtreatment . DNA synthesis
I
￿
was determined as described





The abbreviationsused are : P,
addition offresh basalMcCoy's
5A medium ; P+N1, addition
of fresh basal McCoy's 5A plus TGF-ß, (5 ng/ml) ; P+ß1+Ab, ad-
dition of fresh basal McCoy's 5A medium, TGF-01 (5 ng/ml), and
TGF-ß, neutralizing antibody (10,ug/ml) ; P+Ab, addition offresh
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was essential to the selection of this cell line as a recipient
for the TGF-0 1 antisense expression vector.
Expression of TGF-0, AntisensemRNA
The expression vector (RSVAS) contains a 1.7-kb fragment
of the human TGF-0 1 cDNA which was inserted in an an-
tisense orientation into the mammalian expression vector
RLDN . Transcription of the insert is driven by the Rous Sar-
coma virus LTR promoter placed upstream . The bovine 3'
flanking sequence provides a termination signal for RNA
processing (Fig . 4) . FET cells were transfected with thevec-
tor as described in Materials and Methods and colonies
selected by growth inG418. Resistant colonies toG418 were
obtained within 2-3 wk . We decided to perform our experi-
Figure 4 . Human TGF-01 antisense expression vector, RLDN-
RSVAS. The expression vector contains a 1.7-kb fragment of the
human TGF-ß, cDNA which was inserted in an antisense orienta-
tion into the mammalian expression vector RLDN . Transcription
of the insert is driven by the Rous sarcoma virus long terminal re-
peat promoter. The bovine growth hormone 3'-flanking sequence
provides-a termination signal forRNA processing . A bacterial neo-
mycin phosphotransferase gene (NEO) expression cassette allows
G418 selection .ments with pooled colonies of transfected cells designated
FET RSVAS . Controls were pooled colonies of cells trans-
fected with the vector without the TGF-ß, antisense insert
and designated FET NEO . We decided to use pooled colo-
nies for our experiments because of previous work which
showed a high degree of heterogeneity with respect to TGF-ß,
response among clones of cells from parental colon carci-
noma cell lines (Mulder et al ., 1988) . This heterogeneity
which also extends to TGF-ß expression would be a compli-
cating factor in the analysis of any single clone for TGF-ß,
autocrine effects .
Expression of the TGF-ß, antisense mRNA was deter-
mined by a specific RNase protection assay which generated
a 232-bp protected fragment from a 243-bp sense RNA
probe synthesized by SP6 polymerases in vitro . The levels
of protected fragments from pooled FET RSVAS and three
individual clones (A, B, and I) are shown in Fig . 5 . As ex-
pected, no protection is seen in FET NEO or parental FET
cells. Cells expressing the antisense mRNA had a fivefold
reduction of TGF-ß, mRNA expression as indicated by den-
sitometry of the Northern analysis shown in Fig . 6. TGF-ß,
protein levels were reduced from a level of -40 ng/ml per
72 h/10 6 cells in FET NEO cells to a level below the detec-
tion limits of the assay in FET RSVAS cells .
Southern blot hybridization analysis with the TGF-ß,
cDNA probe (1.2-kb EcoRI fragment of simian TGF-ß,
cDNA) confirmed the presence of the TGF-ß, antisense ex-
pression vector in the FET RSVAS cells . KpnI digestions of
DNA showed a 651-bp fragment which was specific to FET
RSVAS cells and clone B cells (data not shown) .
Repression ofTGF--ß, Expression Reduces Lag TFme in
Cultures ofFETCells
Uncoupling of the TGF-ß1 autocrine loop by neutralizing
antibody led to increased proliferation ofFET cells as shown
above. Therefore, disruption of the autocrine loop by reduc-
tion of TGF-ß, mRNA expression should have similar
effects on the growth of FET cells. It should be noted that
previous work documenting the effects of TGF-ß, neutraliz-
ing antibody on the growth of cancer cells (Arteaga et al.,
1990 ; Hafez et al ., 1990) involved one pointproliferation as-
says similar to the proliferation assay presented in Fig . 2
above. The differences seen in proliferation could be due to
an increase in proliferation rate (reduced doubling time) or
due to a decrease in the time required to achieve logarithmic
growth in tissue culture (reduced lag time) . Constitutive
reduction of TGF-ß, expression in RSVAS transfected FET
cells permitted us to determine whether uncoupling the
TGF-ß, autocrine loop affected doubling time or lag time
by generating growth curves instead of one point assays.
Growth curves for FET RSVAS and FETNEO were gen-
erated in 96-well plates at inocula of 102 and 103 cells, re-
spectively (Fig. 7, A and B) . FET NEO cells show a period
of 8 d before the termination of lag phase at an inoculum of
102 cells (Fig . 7 A) and 5 d at an inoculum of 103 cells (Fig .
7 B) . In contrast, FET RSVAS cells showed a period of 5 d
before the termination of lag phase at an inoculum of 102
cells (Fig . 7 A) and showed no lag period at all when 103
cells were inoculated . Once lag phases were completed no
major differences were observed in the growth rates ofFET
NEO and FET RSVAS cells . These results indicate that the
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Figure 5. Detection of antisense TGF-01 RNA by RNase protec-
tion assay . A 243-bp PvuII-PvuH TGF-ß, cDNA fragment was
cloned into plasmidpGEM3Z (-) to generate the RNA probe. A
uniformly radiolabeled 32psense strand RNA probe was synthe-
sized in vitro by SP6 RNA polymerase . Excess probe was hybrid-
ized in solution with 50 hg of total cellular RNA from TOF-0 1
antisense-transfected FET cells (FET RSVAS), TGF-ß, antisense-
transfected PET clone I, clone A, clone B, vector RLDN-trans-
fected PET cells (FET NEO) or tRNA, and then digested with
RNase as described in Materials and Methods . The protected RNA
probe was fractionated by electrophoresis through a 6%/8 M urea
polyacrylamide gel . All RNA from TGF-ß, antisense-transfected
PET cells protected an expected 232-bp fragment (lane 4, FET
RSVAS ; lane S, cloneA ; lane 6, clone B, and lane 7, clone I) . RNA
from FET NEO cells and tRNA were unable to protect the probe
(lane 8and lane 3) . A pBR322 Msp cut marker (New England Bio-
labs, Inc ., Beverly,MA) and full-length undigested probe are shown
in lanes 1 and 2, respectively. The position expected for a 232-bp
nucleotide fragment is indicated .Figure 6. Northern analysis ofTGF-ß, RNA transcripts . Poly(A)*-
RNA (10 lAg) from parental FET, plasmid vector RLDN and the
TGF-01 antisense expression vector transfected cells were electro-
phoresed on a 1.2%/2.2 M formaldehyde-agarose gel, transferred
into a Nytran filter, and hybridized to a 32plabeled TGF-01 cDNA
probe. Ethidium bromide staining of the gel is shown .
major effect of autocrine TGF-01 on the growth of FET
cells in tissue culture is to reduce the lag time rather than
to increase the rate of proliferation . Northern analysis of
c-myc expression showed no difference in levels of expres-
sion between FET NEO and FET RSVAS cells indicating
that constitutive repression of TGF-,ß, did not affect long-
term steady-state levels of this competence gene (data not
shown) .
These findings are consistent with the effects of exogenous
TGF-01 on the proliferation of FET cells . One-point prolif-
eration analyses have shown that exogenous TGF-0 1 can in-
hibitFET cells as well as several other colon carcinoma cell
lines by as much as 60% (Hoosein et al ., 1989) . Growth
curves were performed to determine whether the effect is on
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Figure 7 . Growth curves forFETNEO andFET RSVAS cells . Cells
were plated at initial numbers of 10 2 (A) or 10 3 (B) in 96-well
plates. Relative cell growth was estimated by the measurement of
absorbance at 540nM after theMTT assay carried out at the indi-
cated times . Values are means ± standard deviations derived from
16 wells .
growth rate or lag time. Results were similar to those de-
scribed above forFET RSVAS cells vs . FET NEO cells . Ex-
ogenous TGF-0 1 caused an extension of lag time relative to
untreated cells at an inoculum of 100 cells . TGF-,ß, was
less effective in causing increased lag time at higher initial
inocula (data not shown) .
Reduction of endogenous TGF-0 1 expression in FET
RSVAS cells should lead to an altered response to ex-
ogenously added TGF-0 1 relative to FET NEO cells . The
removal of endogenous TGF-01 would lead to the expecta-
tion that more exogenous TOF-ß, would have to be added
192Figure 8. Dose response of FET RSVAS and FET NEO cells for
growth inhibition by exogenous TGF-ß1 . (A) FET NEO and FET
RSVAS cells were plated into 96-well plates at 10 2 or 103 cells per
well in growth medium containing the indicated concentrations of
TGF-01 (from 0.1 ng/ml to 5 ng/ml) . After 4 d, the cell growth
wasmeasured by theMTTassay. Thegrowth inhibition is presented
as percentage growth of untreated cultures . Values are the means
f standard deviation derivedfrom 16 wells . (B) Response ofFET
RSVAS cells to exogenous TGF-ß1 in the presence of high concen-
trations of TGF-0 1 (from 0.3 ng/ml to 50 ng/ml) .
to FET RSVAS cells to achievethe same level of inhibition
as that obtained in FETNEO cells . Consequently, dose re-
sponse curves were performed to compare the response of
FET RSVAS and FET NEO cells to exogenous TGF-ß1
(Fig . 8, A andB) . FET NEO cells showed significant levels
of inhibition at as little as 0.2 ng/ml TGF-01 with 50% inhi-
bition ofproliferation at 5 ng/ml (Fig . 8A) .As expectedFET
RSVAS cells required more exogenous TGF-ß1 to achieve
similar levels of inhibition . Only 15% inhibition was ob-
served at 5 ng/ml in FET RSVAS cells (Fig . 8 A) while 50%
inhibition of proliferation required the addition of 25 ng/ml
of exogenous TGF-ß1 (Fig . 8 B) .
Repression ofTGF-01 Enhances the Tumorigenicity of
FET Cells
Anchorage-independent growth in semisolid medium and
the formation of xenografts in immunocompromised mice
are generally regarded as two of themost useful parameters
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in assessing the malignancy of human cells . Since TGF-ß,
acts as a negative regulator ofgrowth and is known to affect
the activity of tumor suppressor genes such as retinoblas-
toma protein (Laiho et al ., 1990), it was hypothesized that
the uncoupling of the TGF-0 1 autocrine loop might lead to
the expression of a more aggressive phenotype than control
cells with an intact autocrine loop . Consequently, we com-
paredthe anchorage-independent growth andtumorigenicity
of FET RSVAS cells with those ofFET NEO cells .
The FET cell line has been shown to grow relatively
poorly in soft agarose (Brattain et al ., 1984) with cloning
efficiencies in the rangeof 1-2% at inocula of 103-104 cells .
We compared anchorage-independent growth ofFET NEO
and FET RSVAS cells at inocula ranging from 102 to 10°
cells. Results from an inoculum of 10° cells are shown in
Fig . 9 . Thecloning efficiency ofFETNEOcellsranged from
1.4 to 1.8% in three plates at this inoculum while FET
RSVAS cells showed cloning efficiencies rangingfrom 5.2 to
6.9% in the same experiment . Average cloning efficiencies
were 1.5 and 6.1%, respectively. In addition to the fourfold
increase in cloning efficiency, the FET RSVAS cells formed
significantly larger colonies. The maximal size for FET
NEO colonies was on the order of 50 cells while approxi-
mately half of the FET RSVAS colonies had colonies with
four- to sixfold more cells as estimated by size .
FETcellshadpreviously beenshownto be weakly tumori-
genic as relatively high inoculawere required forsubcutane-
oustumor formation in athymicnude mice and when tumors
did form therewere relatively long periodsof latencybefore
their appearance (Brattainet al ., 1984) . Increased clonoge-
nicity in soft agaroseby theFET RSVAS cells suggested that
disruption of the TGF-0 1 autocrine loop might also lead to
increased tumorigenicity. To test this hypothesis tumor for-
mation in athymicmice wastested at several inocula ofFET
NEO and FET RSVAS cells ranging from 1.2 x 105 to 2 x
106 . FETNEO cells were tumorigenic only at 2 x 106 cells
as all animals injected at this inoculum formed tumors within
4 wk of subcutaneous injection. Similar results were ob-
tained withFETRSVAS cells. Thetime to reachatumor size
of 0.5 cm in diameter wasthe same forboth control andFET
RSVAS cells (data not shown) suggesting similar growth
rates at high initial inocula . Inocula below 2 x 10 6 FET
NEO cells did not give rise to any tumors within 6 wk of in-
jection(Table I) . In contrast at this inoculum ofFET RSVAS
cells, 80% of animals had tumors by 4 wk and 100% by 6
wk (Table I) . At the next lowest inoculum (5 x 105) 40% of
the animalshadtumors by 6 wk (Table I) . Lowerinoculadid
notgive rise to anytumors within 6 wk . TheB clone ofFET
RSVAS cells which expressed high levels of antisense TGF-
0 1 (see Fig . 5) was more aggressive as all animals injected
with 106 cells showed tumors of 1 cm3 within 4 wk . These
results indicated a significant increase in the tumorigenic
potential of cells in which the TGF-ß1 autocrine loop had
been uncoupled by the expression of TGF-ß1 antisense
mRNA and showed that thenegative autocrine loop is opera-
tional in vivo as well as in vitro.
Discussion
Others have proposed thattheTGF-ßs couldact as autocrine-
negative growth factors (Tucker et al ., 1984). The recent
availability ofTGF-ß neutralizing antibodies has led to the
193Figure 9 . Autocrine effect of TGF-01 on anchorage-independent growth . FET RSVAS and FET NEO cells were seeded at 10° cells/ml
in 0.4% agarose in the serum-free medium and cultured for 2 .5 wk at 37°C with 5% C02 in a humidified incubator . Plates were stained
with a vital tetrazolium dye and photographed as described in Materials and Methods .
development of data which support this hypothesis (Arteaga
et al., 1990 ; Hafez et al., 1990) . However, it has been dif-
ficult to interpret results because most oftheTGF-ß secreted
by cells in tissue culture is in a latent form (Lawrence et
al ., 1985) . It is not clear whether the low levels of activated
TGF-ß, (usually 410%) produced by cell lines are a tissue
culture artifact or whether negative autocrine loops are func-
tional in an in vivo environment . Thus far, the neutralizing
antibody approaches have used increased growth in tissue
culture, increased mitogenesis, and increased clonogenicity
cells as the expected end point of assays for negative TGF-ß
autocrine function . Not surprisingly, the levels of prolifera-
tive increase in these investigations have been modest (Ar-
teaga et al ., 1990) . One explanation for the modest effects
seen previously is that TGF-ß is not the only negative auto-
crine factor present (Arteaga et al ., 1990) . Furthermore,
studies thus far reported on TGF-ß 1 neutralizing antibody
have not dealt with the issue ofwhether the cells under inves-
tigation express TGF-N2 and/or TGF-ß3 and whether the
neutralizing antibody has any effect on the expression of
these members of the TGF-ß family. Compensatory or even
basal expression of other members of the TGF-ß family
could reverse the effect of removing TGF-ß1 from the
system .
To overcome some of the difficulties described above we
have taken the approach of reducing endogenous TGF-ß,
Table I. Tumorigenieity ofFET Cells Expressing
TGF-ß r Antisense in Athymie Nude Mice
8-12-wk-old nu-nu female mice were injected subcutaneously with either 0 .5
x 106 or 1 x 106 FETNEO or FET RSVAS cells . Number of animals with
tumors in each group within the indicated time are presented .
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expression through the constitutive expression of an an-
tisense mRNA to TGF-ß, . This approach allowed for the
generation of more extensive in vitro proliferation data as
well as the unique ability to identify any negative autocrine
function ofTGF-ß1 in vivo . In addition, the recipient colon
carcinoma cell line, FET, was selected for these investiga-
tions because it was shownto express relatively large amounts
of TGF-ß, without expressingTGF-/ß2 or TGF-ß, . Moreover,
reduction of TGF-ß, mRNA by transfection did not lead to
the expression of either TGF-ß2 or TGF-ßs mRNA (data not
shown) . Consequently, the selection ofFET cells for these
experiments circumvented potential complications which
might arise from other members of the TGF-ß family :a the
interpretation of results .
FET cells had several other advantages for these studies .
These included their continuous maintenance in a fully
defined, serum-free, tissue culture medium, which elimi-
nated any potential effects ofTGF-ß binding proteins such as
a macroglobulin (Danielpour et al ., 1989) or effects of un-
known positive or negative growth factors in serum which
could confuse the interpretation of results . Furthermore,
FET cells had the benefit that they were poorly growing in
semisolid medium and did not readily form tumors in nude
mice. As such, these cells, which have been classified as rel-
atively unaggressive compared to other colon carcinoma cell
lines (Brattain et al., 1984 ; Chantret et al ., 1988 ; Mulder
and Brattain, 1989), offered a relatively sensitive model sys-
tem for alterations in tumorigenic properties .
Initially, we provided evidence that FET cells had a nega-
tive TGF-ß, autocrine loop as shown by an increase in
proliferation of 175% and an increase of mitogenesis in the
range of400% (see Figs . 2 and 3) in response to neutralizing
antibodies . These results were similar to those which had
been obtained with otherhuman cancer cells including those
derived from lung (Keski-Oja et al., 1987), breast (Arteaga
et al ., 1990), and colon (Hafez et al ., 1990) .
Cells expressing the TGF-ß, antisense mRNA (FET
RSVAS) also showed similar results as single-point prolifera-
tion assays indicated that elimination ofTGF-l01 expression











FET NEO 1 .0 015 015 015
FET RSVAS 1 .0 015 4/5 515
FET NEO 0 .5 015 015 015
FET RSVAS 0.5 015 015, 2/5constitutive uncoupling of the TGF-ß, negative autocrine
loop in FET RSVAS cells also allowed us to determine
whether the change in proliferation was due to decreased
doubling time or an increase in lag time by generating
detailed growth curves. The results clearly indicated that the
major effect of the TGF-ß, negative autocrine loop in FET
cells was on increased lag time rather than decreased dou-
bling time. Interestingly, the effect of exogenous TGF-ß, on
untransfected parental FET cells is essentially identical .
The length of lag time for cells in tissue culture is gener-
ally regarded to be a function of their ability to condition
their growth medium with positive growth factors such as
TGF-«. Once a critical concentration of positive factors is
achieved, cells go into a logarithmic growth phase. One way
in which TGF-ß, may be acting as a negative regulator in
this system would be to subdue the expressionofpositive fac-
tors which condition the medium. This would have the effect
of delaying the achievement of a critical concentration of
positive factors. Another piece of evidence which is consis-
tent with this explanation is the reduced effect of TGF-ß, on
the inhibition of proliferation and repression of c-myc ex-
pression in colon cancer cells as initial cell density is in-
creased (Mulder and Brattain,1988) . Similarly, FET RSVAS
cellsin log phasegrowth had the same c-myclevels as control
cellsin log phase growth. Finally, Mulder et al. (1990b) have
shown that TGF-ß, treatment of FET cells represses growth
factor mediated induction of TGF-a mRNAin quiescent cells.
Exogenously added TGF-ß, (5 ng/ml) was able to coun-
teract the effect of neutralizing antibody on FET cell prolif-
eration and DNA synthesis. Dose response curves compar-
ing the inhibition of FET NEO and FET RSVAS cells by
TGF-ß, indicated that 3-5 ng/ml TGF-ß, was required be-
fore inhibition ofFET RSVAS cells was detected. Equivalent
inhibition of FET NEO cells was obtained in the range of
0.1-0.3 ng/ml TGF-ß, indicating that the expression of an-
tisense TGF-ß, mRNA had a net effect of reducing auto-
crine TGF-ß, activity by 3-5 ng/ml over the 5-d period of
the proliferation assay. These results are in relatively good
agreement with the requirement for 5 ng/ml TGF-ß, to
overcome neutralizing antibody effects at an antibody con-
centration giving a similar increase in proliferation in paren-
tal FET cells as obtained with the RSVAS cells. It is also in
good agreement with the levels of active TGF-ß, detected in
conditioned medium of FET cells (4 .7 ng/ml) over a 3-d
period.
The differences in anchorage-independent growth between
FET NEO and FET RSVAS cellswere much more dramatic
(see Fig. 9) than the differences in proliferation. While the
difference in cloning efficiency was fourfold, there was also
a substantial difference in the size of the colonies obtained.
The difference in lag time between FET NEO and FET
RSVAS cells could explain part of the difference in cloning
efficiency in this experiment, but does not seem to be ade-
quate to fully explain the dramatic differences observed. The
assay was performed over the course of 3 wk at an inoculum
of 2 x 10° cells, conditions which would seem likely to be
beyond lag time effects. Secondly, as colonies grow to the
size and density seen in FET RSVAS in Fig. 9, there is a
significant nutrient-deprivation effect which retards further
growth. This suggests that potential differences between the
two cell types couldbe greater than those found in this assay.
Repression of TGF-ß, mRNA expression also led to a
higher level of tumorigenicity in athymic nude mice as
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judged by 100% tumor formation at 106 cells relative to the
complete lack oftumor formation by control cells at this in-
oculum. There was also sometumor formation at lower inoc-
ula for the FET RSVAS cells. These results are the first
demonstration that TGF-ß, can function as a negative auto-
crine factor in vivo as well as in tissue culture assays. The
differences in tumor formation by FET cells and FET
RSVAS cells would not seem to be adequately explained by
a simple difference in lag time generated by the presence of
TGF-ß, in the FET NEO cells since parental FET cells
were never found to be tumorigenic at inocula of 106 cells
even when mice were observed for up to 60 d.
FET RSVAS cells showed a fivefold reduction in mRNA
levels of TGF-ß, after transfection with the antisense vec-
tor. Efforts to demonstrate TGF-ß, antisense mRNA by
Northern analysis were unsuccessful and, therefore, a spe-
cific RNase protection assay was developed which did show
that antisense mRNA was expressed. Consequently, it was
not possible from the available data to determine how much
expression of the antisense mRNA was necessary to achieve
the fivefold reduction of TGF-ß, sense mRNA . Further-
more, duplex formation of sense and antisense mRNAin the
cytoplasm was not demonstrated (data not shown). Conse-
quently, it is not clear whether the TGF-ß, levels are re-
duced in FET cells as a result of sense-antisense binding or
whether some other mechanism specifically involving the
expression of TGF-ß, is operational in these cells as has
been shown in other systems (Inouye, 1989; Chadwick,
1988; Kokha et al., 1989). However, the ability of exogenous
TGF-ß, to reverse and neutralizing antibodies to mimic the
effects of antisense expression indicate the specificity of the
TGF-ß, antisense expression vector.
We have developed a large bank of colon carcinoma cell
lines with a broad spectrum of biological properties (Brat-
tain et al., 1984) . FET cells represent one extreme of cells
in this spectrum. As indicated above, they are not tumori-
genic at low inocula and have low cloning efficiencies in soft
agarose (Brattain et al., 1984). Cell lines at the other ex-
treme of the biological spectrum form tumors in 100% of
animals at inocula of 106 cells. Tumors generated at 106
cells grow to 1 cm' within 3 wk. Furthermore, these bio-
logically aggressive cells have cloning efficiencies of -10%
in soft agarose. Consequently, it appears that the effect of un-
coupling the TGF-ß,-negative autocrine loop in FET cells
leads to the generation ofsignificantly more aggressive prop-
erties, but does not result in properties which are as extreme
as those indicated above for the most aggressive coloncarci-
noma cell types. Uncoupling of the loop leads to a cell type
which is intermediate between the two extremes. This is not
surprising since it is likely that there are other negative
growth regulators contributing to the properties of FET
cells. Conversely, there may be higher levels or more types
of positive factors operational in the most aggressive cell
types.
The authors thank Karla Childress-Fields for technical support and Gail
Rudder for preparation of the manuscript.
This work was supported by National Institutes of Health grants CA
45967, CA 50457, and CA 38173 to M . G. Brattain, CA 41233 to R. Ker-
bel, and CA51452 to K. Mulder.
Received for publication 13 August 1991 and in revised form 19 September
1991 .
195References
Arteaga, C. L., R. J. Coffey, Jr., T. C. Dugger, C. M. McCutchen, H. L.
Moses, and R. M. Lyons. 1990. Growth stimulation ofhuman breast cancer
cells with anti-transforming growth factor 0 antibodies: evidence for nega-
tive autocrine regulation by transforming growth factor 0. Cell Growth &
Differ. 1:367-374.
Aviv, H., and P. Leder. 1972. Purification of biologically active globin mes-
senger RNA by chromatography on oligothymidylic acid cellulose. Proc.
Natl. Acad. Sci. USA. 69:1408-1412.
Bascom, C. C., J. R. Wolfshohl, R. J. Coffey, Jr., L. Madison, N. R. Webb,
A. R. Purchio, R. Derynck, and Hp. L. Moses. 1989. Complex regulation
of transforming growth factor ß,, 92, and N3 mRNA expression in mouse
fibroblasts keratinocytes by transforming growth factor ß, and 02. Mol.
Cell. Biol. 9:5508-5515.
Boyd, D., A. E. Levine, D. E. Brattain, M . K. McKnight, and M. G. Brattain.
1988. Comparison ofgrowth requirement oftwo human intratumoral colon
carcinoma cell lines in monolayer and soft agarose. Cancer Res. 48:2469-
2474.
Brattain, M. G., M. E. Marks, J. McCombs, W. Finely, and D. E. Brattain.
1983. Characterization of human colon carcinoma cell lines isolated from a
single primary tumor. Br. J. Cancer. 47:373-381.
Brattain, M. G., A. E. Levine, S. Chakrabarty, L. Yeoman, J. K. V. Willson,
and B. H. Long. 1984. Heterogeneit y of human colon carcinoma. Cancer
Metastasis Rev. 3:177-191.
Carmichael, J., W. G. DeGraff, A. F. Gazdar, J. D. Minna, andJ. B. Mitchell.
1987. Evaluation ofa tetrazolium-based semisutomated colorimetric assay:
assessment of chemosensitivity testing. Cancer Res. 47 :936-942.
Chadwick, D. E., and A. E. Lagarde. 1988. Coincidental acquisition ofgrowth
autonomy and metastatic potential during the malignant transformation of
factor-dependent CCL39 lung fibroblasts. J. Natl. CancerInst. 80:318-325.
Chantret, I., A. Barbat, E. Dussaulx, M. G. Brattain, andA. Zweibaum. 1988.
Epithelial polarity, villin expression, and enterocytic differentiation of cul-
tured human colon carcinoma cells: a survey of twenty cell lines. Cancer
Res. 48 :1936-1942.
Chirgwin, J. M., A. E. Przybyla, R. J. MacDonald, and W. J. Rutter. 1979.
Isolation of biologically active ribonucleic acid from sources enriched in
ribonuclease. Biochemistry. 18 :5294-5299.
Danielpour, D., L. L. Dart, K. C. Flanders, A. B. Roberts, and M. B. Sporn.
1989. Immunodetection and quantitation of the two forms of transforming
growth factor-beta (TGF-ß, and TGF-02) secreted by cells in culture. J.
Cell. Physiol. 138:79-86.
Derynck, R., J. A. Jarrett, E. Y. Chen, D. H. Eaton, J. R. Bell, R. K. Assoian,
A. B. Roberts, M. B. Sporn, and D. V. Goeddel. 1985. Human transforming
growth factor-ß complementary DNA sequence and expression in normal
and transformed cells. Nature (Lond.). 316:701-705.
Derynck, R., P. B. Lindquist, A. Lee, D. Wen, J. Tamm, J. L. Graycar, L.
Rhee, A. J. Mason, D. A. Miller, R. J. Coffey, Jr., H. L. Moses,qand E. Y.
Chen. 1988. A new type of transforming growth factor ß, TGF-N3 . EMBO
(Eur. Mol. Biol. Organ.) J. 7:3737-3743 .




1989. Retinoic acid induces transforming growth factor-N2 in cultured ker-
atinocytes and mouse epidermis. Cell Regulation. 1:87-97.
Gorman, C. M., G. T. Merlino, M . C. Willingham, I. Pastan, and B. H.
Howard. 1982. The Rous sarcoma virus long terminal repeat is a strong pro-
moter when introduced into a variety of eucaryotic cells by DNA-mediated
transfection. Proc. Natl. Acad. Sci. USA. 79:6777-6781 .
Graycar, J. L., D. A. Miller, B. A. Arrick, R. M. Lyons, H. L. Moses, and
R. Derynck. 1989. Human transforming growth factor-N3: recombinant ex-
pression, purification, and biological activities incomparison with trans-
forming growthfactors-01 and 02. Mol. Endocrinol. 3 :1977-1989.
Hafez, M. M., D. Infante, S. Winawer, and E. Friedman. 1990. Transforming
growth factor-$, acts as an sutocrine-negative growth regulator in colon en-
terocytic differentiation but not in goblet cell maturation. Cell Growth &
Differ. 1:617-626.
Hoosein, N. M., D. E. Brattain, M. K. McKnight, A. E. Levine, and M. G.
Brattain. 1987 . Characterization of the inhibitory effects of transforming
growth factor-0 on a human colon carcinoma cell line. Cancer Res. 47:
2950-2954.
Hoosein, N. M., M. K. McKnight, A. E. Levine, K. M. Mulder, K. E. Chil-
dress, D. E. Brattain, and M. G. Brattain. 1989. Differentia l sensitivity of
subclasses of human colon carcinoma cell lines to the growth inhibitory
effects of transforming growth factor-ß,. Exp. Cell. Res. 181 :442-453 .
The Journal of Cell Biology, Volume 116, 1992
Inouye, M. 1989. Anti-sense RNA: Its functions and applications in gene
regulation-a review. Gene (Amst.). 72:35-45.
Keski-Oja, J., R. M. Lyons, and H. L. Moses. 1987. Immunodetection and
modulation of cellular growth with antibodies against native transforming
growth factor-ß,. Cancer Res. 47:6451-6458.
Khokha, R., P. Waterhouse, S. Yagel, P. I. Lala, C. M. Overall, G. Norton,
and D. T. Denhardt. 1989. Anti-sense RNA-induced reduction in routine
TIMP levels confers oncogenicity on Swiss 3T3 cells. Science (Wash. DC).
243:947-950.
Laiho, M., J. A. DeCaprio, W. J. Ludlow, D . M. Livingston, andJ. Massague.
1990. Growth inhibition by TGF-,6 linked to suppression of retinoblastoma
protein phosphorylation. Cell. 62:175-185.
Lawrence, D. A., R. Pitcher, and P. Jullien. 1985. Conversionofhigh molecu-
lar weight latent 0-TGF from chicken embryo fibroblasts into a low molecu-
lar weight active 9-TGF under acidic conditions. Biochem. Biophys. Res.
Commun. 133:1026-1034.
Massague, J. 1990. The transforming growth factor-0 family . Annu. Rev. Cell
Biol. 6:597-641 .
Mulder, K. M. 1991 . Differential regulation ofc-myc and transforming growth
factor-a messenger RNA expression in poorly differentiated and well-
differentiated colon carcinoma cells during the establishment of a quiescent
state. Cancer Res. 51:2256-2262.
Mulder, K. M., and M. G. Brattain. 1988. Alterations in c-myc expression in
relation to maturational status ofhuman colon carcinoma cells. Int. J. Can-
cer. 42:64-70.
Mulder, K. M., and M . G. Brattain. 1989. Effects of growth stimulatory factors
on mitogenicity and c-myc expression in poorly differentiated and well
differentiated human colon carcinoma cells. Mol. Endocrinol. 3:1215-1222 .
Mulder, K. M., L. E. Humphrey, H. G. Choi, K. E. Childress-Fields, and
M. G. Brattain. 1990x. Evidence for c-myc in the signalling pathway for
TGF-,6 in well-differentiated human colon carcinoma cells. J. Cell. Physiol.
145:501-507.
Mulder, K. M., Q. Zhong, H. G. Choi, L. E. Humphrey, and M. G. Brattain.
19906. Inhibitor y effects oftransforming growth factor-ß, on mitogenic re-
sponse, transforming growth factor-a, and c-mycin quiescent, well-differen-
tiated colon carcinoma cells. Cancer Res. 50:7581-7586.
Pharr, D. S., G. Sathe, and M. E. Reff. 1985. A highly modular cloning vector
forthe analysisofeucaryotic genes and gene regulatoryelements. DNA (N1).
4:461-467.
Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Analysis and cloning of
eukaryotic genomic DNA. Molecular Cloning. 2:9.1-9.59.
Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-
terminating inhibitors. Proc. Natl. Acad. Sci. USA. 74:5463-5467.
Shaeffer, W. I., and K. Friend. 1976. Efficient detection of soft agar grown
colonies using a tetrazolium salt. Cancer Len. 1 :259-262.
Sharpies, K., G. D. Plowman, T. M. Rose, D. R. Twardzik, and A. F. Purchio.
1987. Cloning and sequenceanalysis of simian transforming growth factor-ß
cDNA. DNA (NI9. 6:239-244.
Singh, G. K., F. W. Ruscetti, M. Beckwith, J. R. Keller, L. Ellingsworth,
W. J. Urba, and D. L. Longo. 1990. Growth inhibition of a human lym-
phoma cell line: induction of a transforming growth factor-0 mediated auto-
crine negative loop by phorbol myristate acetate. Cell Growth & Differ.
1 :549-557.
Southern, P. J., and P. Berg. 1982 . Transformation ofmammalian cells to anti-
biotic resistance with a bacterial gene under the control ofthe SV40 early
region promoter. J. Mol. Appl. Genet. 1:327-341.
Sporn, M. B., A. B. Roberts, L. M. Wakefield, and B. de Crombrugghe. 1987.
Some recent advances in the chemistry and biology oftransforming growth
factor beta. J. Cell Biol. 105:1039-1045.
Tucker, R. F., G. D. Shipley, H. L. Moses, and R. W. Holley. 1984. Growth
inhibitor fromBSC-1 cells is closely related to theplatelet type $ transform-
ing growth factor. Science (Wash. DC). 226:705-707 .
Wan, C.-W., M. K. McKnight, D. E. Brattain, M. G. Brattain, and L. C . Yeo-
man. 1988. Different epidermal growth factor responses and receptor levels
in human colon carcinoma cells. Cancer Lett. 43:139-143.
Wood, W. I., J. Gitschier, L. A. Lasky, and R. M. Lawn. 1985. Base composi-
tion dependent hybridization in tetro-methylammonium chloride: a method
for oligonucleotide screening ofhighly complex gene libraries. Proc. Nati.
Acad. Sci. USA. 82:1585-1588.
Zinn, K., D. Dimaio, and T. Maniatis. 1983. Identification of two distinct
regulatory regions adjacent to the human 0-interferon gene. Cell. 34:865-
879.
196